Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAC vs CMF in Stage III Breast Cancer
NCT00002696Phase 3Suspended
- Sponsor
- Grupo Oncológico Cooperativo del Sur
- Start
- Oct 1995
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclophosphamide, doxorubicin, fluorouracil and methotrexate in breast cancer (2 arms), sponsored by Grupo Oncológico Cooperativo del Sur. Primary endpoint: Objective Response Rate. Started Oct 1995; status: suspended.
02
Drugs
cyclophosphamidedoxorubicinfluorouracilmethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002696.